000186448 001__ 186448
000186448 005__ 20210129214908.0
000186448 037__ $$aFZJ-2015-00522
000186448 041__ $$aEnglish
000186448 082__ $$a610
000186448 1001_ $$0P:(DE-Juel1)131773$$aGeisler, Stefanie$$b0$$eCorresponding Author$$ufzj
000186448 245__ $$aIsomers of 4-[18F]fluoro-proline: radiosynthesis, biological evaluation and results in humans using PET
000186448 260__ $$aSharjah$$bBentham Science Publ.$$c2014
000186448 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1421654904_11842
000186448 3367_ $$2DataCite$$aOutput Types/Journal article
000186448 3367_ $$00$$2EndNote$$aJournal Article
000186448 3367_ $$2BibTeX$$aARTICLE
000186448 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000186448 3367_ $$2DRIVER$$aarticle
000186448 520__ $$aProline and hydroxyproline represent major constituents of mammalian structural proteins, especially of collagen. An efficient radiosynthesis of the (18)F-labeled proline derivatives cis-/trans-4-[(18)F]fluoro-L-proline was developed two decades ago with the aim to investigate various diseases with altered collagen synthesis using Positron-Emission- Tomography (PET). A number of studies have explored cis-4-[(18)F]fluoro-L-proline uptake in various pathologies associated with increased collagen formation and in neoplastic lesions, but so far the results have not been very promising. Trans-4-[(18)F]fluoro-L-proline has not yet been investigated in detail, however the compound exhibits considerable differences in metabolic behavior and biodistribution compared with its cis-enantiomer. In recent years, the D-isomers of cis- /trans-4-[(18)F]fluoro-proline have been considered as PET tracers as well, and it was observed that both exhibit a preferred uptake into the brain compared with their L-isomers. Surprisingly, a high uptake of cis-4-[(18)F]fluoro-D-proline was found in brain areas exhibiting secondary neurodegeneration as well as in areas of radionecrosis after treatment of brain tumors. In this article, the present knowledge on the biological and physiological properties of cis-/trans-4-[(18)F]fluoro-D/L-proline and the results in various pathologies are reviewed, including some previously unpublished results from our laboratory.
000186448 536__ $$0G:(DE-HGF)POF2-333$$a333 - Pathophysiological Mechanisms of Neurological and Psychiatric Diseases (POF2-333)$$cPOF2-333$$fPOF II$$x0
000186448 536__ $$0G:(DE-HGF)POF2-89572$$a89572 - (Dys-)function and Plasticity (POF2-89572)$$cPOF2-89572$$fPOF II T$$x1
000186448 7001_ $$0P:(DE-Juel1)131818$$aErmert, Johannes$$b1$$ufzj
000186448 7001_ $$0P:(DE-Juel1)131627$$aStoffels, Gabriele$$b2$$ufzj
000186448 7001_ $$0P:(DE-Juel1)144347$$aWilluweit, Antje$$b3$$ufzj
000186448 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b4$$ufzj
000186448 7001_ $$0P:(DE-Juel1)141877$$aFilss, Christian$$b5$$ufzj
000186448 7001_ $$0P:(DE-Juel1)131794$$aShah, N. J.$$b6$$ufzj
000186448 7001_ $$0P:(DE-Juel1)131816$$aCoenen, Heinrich Hubert$$b7$$ufzj
000186448 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b8$$ufzj
000186448 773__ $$0PERI:(DE-600)2433114-4$$p123-132$$tCurrent radiopharmaceuticals$$v7$$x1874-4710$$y2014
000186448 909CO $$ooai:juser.fz-juelich.de:186448$$pVDB
000186448 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131773$$aForschungszentrum Jülich GmbH$$b0$$kFZJ
000186448 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131818$$aForschungszentrum Jülich GmbH$$b1$$kFZJ
000186448 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131627$$aForschungszentrum Jülich GmbH$$b2$$kFZJ
000186448 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)144347$$aForschungszentrum Jülich GmbH$$b3$$kFZJ
000186448 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich GmbH$$b4$$kFZJ
000186448 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)141877$$aForschungszentrum Jülich GmbH$$b5$$kFZJ
000186448 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131794$$aForschungszentrum Jülich GmbH$$b6$$kFZJ
000186448 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131816$$aForschungszentrum Jülich GmbH$$b7$$kFZJ
000186448 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich GmbH$$b8$$kFZJ
000186448 9132_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000186448 9131_ $$0G:(DE-HGF)POF2-333$$1G:(DE-HGF)POF2-330$$2G:(DE-HGF)POF2-300$$3G:(DE-HGF)POF2$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lFunktion und Dysfunktion des Nervensystems$$vPathophysiological Mechanisms of Neurological and Psychiatric Diseases$$x0
000186448 9131_ $$0G:(DE-HGF)POF2-89572$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$v(Dys-)function and Plasticity$$x1
000186448 9141_ $$y2014
000186448 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000186448 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000186448 920__ $$lyes
000186448 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000186448 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000186448 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x2
000186448 980__ $$ajournal
000186448 980__ $$aVDB
000186448 980__ $$aI:(DE-Juel1)INM-3-20090406
000186448 980__ $$aI:(DE-Juel1)INM-4-20090406
000186448 980__ $$aI:(DE-Juel1)INM-5-20090406
000186448 980__ $$aUNRESTRICTED
000186448 981__ $$aI:(DE-Juel1)INM-4-20090406
000186448 981__ $$aI:(DE-Juel1)INM-5-20090406